U.S. Markets closed
  • S&P Futures

    3,902.00
    +4.25 (+0.11%)
     
  • Dow Futures

    31,241.00
    +39.00 (+0.12%)
     
  • Nasdaq Futures

    11,838.00
    -40.25 (-0.34%)
     
  • Russell 2000 Futures

    1,771.50
    -3.40 (-0.19%)
     
  • Crude Oil

    110.35
    +0.46 (+0.42%)
     
  • Gold

    1,845.10
    +3.90 (+0.21%)
     
  • Silver

    21.87
    -0.03 (-0.13%)
     
  • EUR/USD

    1.0562
    -0.0026 (-0.2429%)
     
  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     
  • Vix

    29.43
    +0.08 (+0.27%)
     
  • GBP/USD

    1.2495
    +0.0020 (+0.1587%)
     
  • USD/JPY

    127.8500
    +0.0560 (+0.0438%)
     
  • BTC-USD

    29,611.37
    +488.49 (+1.68%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     
  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     
  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Dicerna Pharmaceuticals (NASDAQ:DRNA) stock is surging higher on Thursday following news of a massive deal with Novo Nordisk.

Image of two business people shaking hands representing DRNA Stock.
Image of two business people shaking hands representing DRNA Stock.

Source: Shutterstock

The deal will have Novo Nordisk acquiring Dicerna Pharmaceuticals for $38.25 per share. That’s an 80% premium over the stock’s closing price on Wednesday and the purchase will be made with cash.

That’s quite the offer for DRNA stock and it represents a total equity value of $3.3 billion. The deal will have a Novo Nordisk subsidiary initiating a tender offer to acquire all outstanding shares of Dicerna Pharmaceuticals stock.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Once the tender offer is complete, Dicerna Pharmaceuticals will merge with the Novo Nordisk subsidiary. Any shares not part of the offer will be canceled and converted into a right to receive the same $38.25 cash payment.

Both the Board of Directors at Dicerna Pharmaceuticals and Novo Nordisk have given their full support to the acquisition deal. So long as there are no customary closing issues, the deal is set for completion in the fourth quarter of 2021.

Douglas Fambrough, Ph.D., founder, president and CEO of Dicerna Pharmaceuticals, said in a press release announcing today’s news.

“Since the start of our collaboration two years ago, the Dicerna and Novo Nordisk teams have established a strong rapport built on a foundation of mutual respect for one another’s capabilities, culture and expertise.”

News of the acquisition deal has DRNA stock experiencing heavy trading today. That has some 18 million shares of the stock trading hands. This is quite the leap from its daily average trading volume of about 769,000 shares.

DRNA stock was up 78.6% as of Thursday morning.

There’s more recent stock market news to sink your teeth into below!

InvestorPlace offers the latest stock market coverage that traders need to know about today. Among that is talk of a Prime Blockchain SPAC merger, Sono Motors (NASDAQ:SEV) soaring after its IPO, a swell as what has Clover Health (NASDAQ:CLOV) falling today. You can get all those details from the following links!

More Thursday Stock Market News

On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

More From InvestorPlace

The post DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today appeared first on InvestorPlace.